ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
Alto Neuroscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$22.82+0.88 (+4.01%)
Close on Oct 19, 2026
- Market cap
- $976.99M
- P/E (TTM)
- –
- Dividend yield
- –
Alto Neuroscience, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -41.8%
Financial strength
- Current ratio
- 14.85
- Debt to equity
- 0.07
- Debt to assets
- 6.4%
- Cash to current liabilities
- 1463.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.46
- Dividend yield
- –